Author: Tom Wilemon
Jan. 5, 2022—A folic acid-like drug changed a DNA process within brain tumors of glioblastoma patients, according to results from a phase 1 clinical trial.
Study of fully vaccinated patients with cancer who had breakthrough COVID-19 shows 13% mortality rate
Dec. 24, 2021—New research finds that fully vaccinated patients with cancer who had breakthrough COVID-19 infections remained at high risk for hospitalization and death.
Dec. 14, 2021—Vanderbilt research has revealed some of the mechanisms by which polyps develop into colorectal cancer, setting the framework for improved surveillance for the cancer utilizing precision medicine.
Dec. 2, 2021—Vanderbilt's Sonya Reid, MD, MPH, has been selected to participate in the first cohort of the Bristol Myers Squibb Foundation Clinical Trial Diversity Career Development Program.
Nov. 18, 2021—A team of Vanderbilt employees have received and award for implementing a streamlined follow-up protocol for patients who may not know they have cancer.
Nov. 18, 2021—Chic Awearness, a fashion show and fundraiser for ovarian cancer research, returns as an in-person event from 6:30 p.m. to 8:30 p.m. on Monday, Dec. 6.
Nov. 4, 2021— by Tom Wilemon Clint Koerkenmeier, MHS, RN, is the new associate nursing officer at Vanderbilt-Ingram Cancer Center (VICC) with the responsibility for supervising the ambulatory oncology nursing enterprise. He came to Vanderbilt from MD Anderson Cancer Center following the departure of his predecessor, Anna Rodriguez, MSN, MHA, RN, who is now chief nursing officer...
Oct. 28, 2021—Vanderbilt's Sonya Reid, MD, MPH, is a recipient of an NRG Oncology Underserved Minority Scholars Award.
Oct. 28, 2021—Ingrid Mayer, MD, MSCI, is departing Vanderbilt University Medical Center for a new role as an executive with AstraZeneca.
Oct. 21, 2021—Vanderbilt-Ingram Cancer Center is leading an ambitious project to assess the impact of environmental exposures on cancer risk for people living in Southern states.
Oct. 14, 2021—Vanderbilt-Ingram Cancer Center is recruiting patients for a clinical trial using photoimmunotherapy for recurrent head and neck cancer.
Sep. 30, 2021—Vanderbilt-Ingram Cancer Center research is providing new insights into how genetic variants convey breast cancer susceptibility by altering the transcription factor proteins that convert DNA strands into RNA.